Cargando…

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder

INTRODUCTION: We report a case of deterioration of bladder compliance after botulinum toxin type A injection and discontinuation of medication for overactive bladder. CASE PRESENTATION: A female patient with overactive bladder in her sixties had been visiting our outpatient clinic regularly for 4 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Naoki, Ishikawa, Mayumi, Nagabuchi, Masaya, Makino, Shogo, Miyauchi, Kotona, Abe, Noriyuki, Kakizaki, Hidehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436694/
https://www.ncbi.nlm.nih.gov/pubmed/36090943
http://dx.doi.org/10.1002/iju5.12496
Descripción
Sumario:INTRODUCTION: We report a case of deterioration of bladder compliance after botulinum toxin type A injection and discontinuation of medication for overactive bladder. CASE PRESENTATION: A female patient with overactive bladder in her sixties had been visiting our outpatient clinic regularly for 4 years. She had received posterolateral spondylus fusion twice, which resulted in a compression fracture. She had been receiving a combination therapy of anticholinergics and β3‐adrenoceptor agonist for the management of overactive bladder. She received botulinum toxin type A injection for refractory overactive bladder and discontinued medical treatment for overactive bladder. Three months after botulinum toxin type A injection, cystometry revealed the deterioration of bladder compliance. Renal dysfunction, hydronephrosis, and vesicoureteral reflux were shown. Renal function and hydronephrosis were improved after restarting anticholinergics and β3‐adrenoceptor agonist therapy and inserting a temporary transurethral catheter. CONCLUSION: Deterioration of bladder compliance may occur after botulinum toxin type A injection and discontinuation of overactive bladder medication in some patients with underlying neurological disease.